CVS Health Launches Company To Produce Cheaper Versions of Expensive Biotech Drugs

August 24, 2023

CVS Health has introduced Cordavis, a new subsidiary aimed at producing and commercializing “biosimilar” drugs, which are more affordable versions of costly brand prescriptions derived from biotechnology. Cordavis will collaborate directly with drug manufacturers to develop and distribute these biosimilar products, which are approved by the FDA as highly similar and without clinically meaningful differences from existing brand biologic medicines. CVS aims to ensure a consistent and affordable supply of these biosimilars to enhance patient accessibility to vital treatments while reducing costs.

Recent News

China’s Property Market Boost: Stocks Surge, Copper Hits Highs

The Chinese government unveiled a comprehensive support package that has sent ripples through financial markets. This initiative includes a slew of measures aimed at stimulating housing demand and addressing the excess inventory burdening developers. The immediate impact was a significant rally in Chinese stocks and a surge in commodity prices, notably copper, which hit record highs.